Lixte Biotechnology Holdings Inc (LIXTW) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Lixte Biotechnology Holdings Inc (LIXTW) has a cash flow conversion efficiency ratio of -0.189x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-926.75K) by net assets ($4.91 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Lixte Biotechnology Holdings Inc - Cash Flow Conversion Efficiency Trend (2005–2024)
This chart illustrates how Lixte Biotechnology Holdings Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Lixte Biotechnology Holdings Inc (LIXTW) total liabilities for a breakdown of total debt and financial obligations.
Lixte Biotechnology Holdings Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Lixte Biotechnology Holdings Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Jasmine International Public Company Limited
F:JASN
|
0.020x |
|
Spiritus Mundi PLC
LSE:SPMU
|
N/A |
|
Biocept Inc.
NASDAQ:BIOCQ
|
-10.641x |
|
Future Supply Chain Solutions Limited
NSE:FSC
|
0.127x |
|
Housing Development and Infrastructure Limited
NSE:HDIL
|
-0.042x |
|
Rompetrol Rafi
RO:RRC
|
0.103x |
|
Pyxis Tankers Inc
NASDAQ:PXSAW
|
0.033x |
|
Ordinary Fully Paid Deferred Settlement
AU:EDEDA
|
-1.051x |
Annual Cash Flow Conversion Efficiency for Lixte Biotechnology Holdings Inc (2005–2024)
The table below shows the annual cash flow conversion efficiency of Lixte Biotechnology Holdings Inc from 2005 to 2024. For the full company profile with market capitalisation and key ratios, see LIXTW market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $827.22K | $-3.16 Million | -3.826x | -255.95% |
| 2023-12-31 | $3.99 Million | $-4.29 Million | -1.075x | -20.37% |
| 2022-12-31 | $5.17 Million | $-4.61 Million | -0.893x | -3.24% |
| 2021-12-31 | $4.79 Million | $-4.14 Million | -0.865x | -103.37% |
| 2020-12-31 | $5.01 Million | $-2.13 Million | -0.425x | +38.17% |
| 2019-12-31 | $2.43 Million | $-1.67 Million | -0.688x | -87.80% |
| 2018-12-31 | $4.13 Million | $-1.51 Million | -0.366x | +74.19% |
| 2017-12-31 | $995.04K | $-1.41 Million | -1.419x | +81.83% |
| 2016-12-31 | $214.76K | $-1.68 Million | -7.811x | -11.85% |
| 2015-12-31 | $312.33K | $-2.18 Million | -6.983x | -13.52% |
| 2014-12-31 | $265.86K | $-1.64 Million | -6.152x | -23.17% |
| 2013-12-31 | $236.27K | $-1.18 Million | -4.995x | -518.00% |
| 2012-12-31 | $1.49 Million | $-1.21 Million | -0.808x | +95.30% |
| 2011-12-31 | $79.02K | $-1.36 Million | -17.206x | -3090.42% |
| 2010-12-31 | $1.74 Million | $-936.39K | -0.539x | -9.91% |
| 2009-12-31 | $1.30 Million | $-638.44K | -0.491x | -126.56% |
| 2008-12-31 | $-323.55K | $-597.69K | 1.847x | +199.06% |
| 2007-12-31 | $376.93K | $-702.87K | -1.865x | -163.47% |
| 2006-12-31 | $626.56K | $-443.45K | -0.708x | -116.94% |
| 2005-12-31 | $-7.87K | $-32.87K | 4.177x | -- |
About Lixte Biotechnology Holdings Inc
Lixte Biotechnology Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colorectal cancer. The company's LB-100 combined with doxorubi… Read more